Idiopathic Pulmonary Fibrosis Treatment Market
According to the latest report by IMARC Group, titled "Idiopathic Pulmonary Fibrosis Treatment Market : Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," The global idiopathic pulmonary fibrosis treatment market reached a value of US$ 3,278 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 5,268 Million by 2027, exhibiting at a CAGR of 7.89% during 2022-2027.
Idiopathic pulmonary fibrosis (IPF) is severe interstitial pneumonia that is mainly characterized by the formation of scar tissue within the lungs, which causes insufficient delivery of oxygen to the body parts and difficulties in breathing. It is diagnosed via blood tests, lung biopsies, chest imaging studies, computer tomography (CT) scans, antibody tests, pulmonary function tests, etc. IPF can be treated using anti-fibrotic drugs and supportive remedy options, including oxygen therapy, pulmonary rehabilitation, palliative care, etc. As a result, IPF treatment finds widespread applications in hospitals, medical clinics, long-term care facilities, etc., across countries.
Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The escalating prevalence of fibrotic diseases, particularly among the geriatric population, is one of the primary factors driving the idiopathic pulmonary fibrosis treatment market. Besides this, the rising consumption of nicotine-based products, the inflating pollution, and the increasing stress levels among consumers are further augmenting the market growth. Apart from this, various technological advancements in the IPF diagnostic techniques that aid in reducing the risk of acute respiratory deterioration, providing comfort to patients, improving the chances of recovery, enhancing lung functioning, etc., are also catalyzing the global market. Moreover, the launch of favorable policies by the government bodies for the expansion of existing healthcare systems is acting as another significant growth-inducing factor. Furthermore, the elevating research and development (R&D) activities aimed at the introduction and commercialization of novel medicines are expected to propel the idiopathic pulmonary fibrosis treatment market in the coming years.
Request Free Sample Report:
www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market/requestsample
Idiopathic Pulmonary Fibrosis Treatment Market 2022-2027 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.
The report has segmented the market on the basis on region, drug class and end user.
Breakup by Drug Class:
MAPK Inhibitors
Tyrosine Inhibitors
Autotaxin Inhibitors
Breakup by End User:
Hospitals
Long-term Care Facilities
Others
Breakup by Region:
North America: United States, Canada
Asia Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
Latin America: Brazil, Mexico, Other
Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
Market Performance (2016-2021)
Market Outlook (2022- 2027)
Porter's Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
This release was published on openPR.
